Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of July 14, 2026, CYTK trades at $84.05 with a market cap of $11.17B and a P/E ratio of -11.91. CYTK moved -0.41% today. Year to date, CYTK is +28.94%; over the trailing twelve months it is +112.36%. Its 52-week range spans $29.31 to $88.31. Analyst consensus is strong buy with an average price target of $107.21. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CYTK combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $84.05 |
| Market Cap | $11.17B |
| P/E Ratio | -11.91 |
| EPS | $-6.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $88.31 |
| 52-Week Low | $29.31 |
| Volume | 1.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $105.81M |
| Net Income | $-829.61M |
| Gross Margin | 0.00% |
15 analysts cover CYTK: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $107.21.